Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The inspection was carried out between May 26, 2025 and May 31, 2025
Alembic receives EIR from USFDA for facility at Panelav
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Subscribe To Our Newsletter & Stay Updated
